Cardiff Oncology (CRDF) Stock Forecast & Price Target

Cardiff Oncology Inc. is advancing its clinical-stage programs, particularly focusing on onvansertib, a PLK1 inhibitor, which has shown promising responses across the KRAS mutation spectrum in RAS-mutated metastatic colorectal cancer (mCRC) and other significant cancer indications. The increasing probability of regulatory approval for onvansertib has been raised to 40%, reflecting confidence in its potential to transform standard treatment approaches in oncology, especially given the company's focus on high-unmet medical needs. The positive data generated thus far supports a favorable outlook for Cardiff Oncology, potentially increasing its attractiveness as an acquisition target should results continue to demonstrate efficacy in pivotal trials.

Cardiff Oncology faces significant financial challenges, as evidenced by projected net losses of $0.89 per share in 2025 and $0.95 per share in 2024, indicating ongoing operational difficulties. The reliance on the clinical success of onvansertib poses additional risks, including potential delays in pivotal studies and the possibility of receiving negative clinical results, which could undermine the company's market position. Furthermore, concerns surrounding market penetration and competition, coupled with the likelihood of medium-term dilution risks, contribute to an overall negative outlook for the company's stock.